Article Abstract

IDH mutational status and the immune system in gliomas: a tale of two tumors?

Authors: Bryan D. Choi, William T. Curry

Abstract

Gliomas are the most common type of primary brain tumor and include glioblastoma (GBM), which is the most lethal form of the disease, and remains a significant, unmet clinical need (1). Contrary to conventional notions of central nervous system immune-privilege, there is indeed extensive cross-talk between the immune system and tumors in the brain. Several successful immune therapies are either in development or have received recent approval from the Food and Drug Administration across a broad array of cancers (Table 1). However, the results for immune therapy against solid tumors in the brain have been less dramatic to date.